Semax
unknown riskAlso: ACTH 4-7 Pro8Gly9Pro10 · N-Pro-Gly-Pro
Semax is a synthetic heptapeptide derived from the ACTH 4-10 fragment, developed at Moscow State University. Registered in Russia for cognitive enhancement and stroke treatment, it has a strong neuroprotective profile driven primarily by BDNF (brain-derived neurotrophic factor) upregulation.
Reported Benefits
BDNF Upregulation
Consistently demonstrated BDNF increase in multiple animal and human studies.
Stroke Recovery
Russian clinical trials show improved neurological outcomes post-ischemic stroke.
Cognitive Enhancement
Improved memory, attention, and processing speed in clinical studies.
Mechanism of Action
Semax activates melanocortin receptors and dramatically increases BDNF expression — both acutely (within hours) and chronically. It also influences the enkephalinase system, modulates dopaminergic and serotonergic signaling, and has anti-inflammatory effects in neural tissue.
Key Clinical Studies
Kolomin T et al. (2013)
animal · Rat stroke model
Improved neurological recovery and BDNF expression
Gusev EI et al. (1997)
RCT · Ischemic stroke patients
Improved neurological outcomes vs control
Overview
Semax is the most widely used nootropic peptide in Russia, where it is available by prescription for stroke rehabilitation and is used off-label extensively for cognitive enhancement. Its mechanism — primarily through BDNF upregulation — aligns with one of the most robust neurotrophic pathways in the brain.
BDNF as the Key Mechanism
BDNF (brain-derived neurotrophic factor) is essential for neuronal survival, synaptic plasticity, and memory formation. Chronic stress, aging, and neurological disease all reduce BDNF. Semax’s ability to reliably increase BDNF — with a strong signal-to-noise ratio in preclinical and preliminary clinical data — is its most compelling mechanism.
Stroke Application
The Russian clinical data for stroke rehabilitation is the most clinically meaningful evidence for semax. Ischemic stroke creates a therapeutic window where neuroprotective and neurotrophic interventions can limit damage and promote recovery. The BDNF-upregulating mechanism is mechanistically rational for this indication.
Nootropic Use
Off-label use for ADHD, brain fog, and cognitive optimization is widespread in biohacking communities. The evidence for these applications is largely anecdotal, extrapolated from the clinical data and BDNF mechanism.
Regulatory Status
Research OnlyRegistered medicine in Russia; no FDA/EMA approval
Safety Profile
Side Effects
- •Nasal irritation
- •Headache (transient)
- •Agitation (high doses)
Contraindications
- •Bipolar disorder (relative — stimulant properties)
- •Epilepsy
Drug Interactions
- •Psychostimulants (additive)
- •MAOIs
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Semax?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →